Stress hormones promote growth of B16-F10 melanoma metastases: An interleukin 6- and glutathione-dependent mechanism

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Valles, Soraya L ^a   Benlloch, María ^b   Rodriguez, María L ^a   Mena, Salvador ^a   Pellicer, José A ^a   Asensi, Miguel ^a   Obrador, Elena ^a   Estrela, José M ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

Author keywords

Apoptosis; Glutathione; Interleukin 6; Metastases; Stress hormones

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MIFEPRISTONE; NORADRENALIN; PROPRANOLOL; RED FLUORESCENT PROTEIN; SMALL INTERFERING RNA; STRESS HORMONE; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL SELECTION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CYTOKINE RELEASE; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOPHYSIS ADRENAL SYSTEM; IN SITU HYBRIDIZATION; IN VITRO STUDY; LIVER METASTASIS; LUNG METASTASIS; MALE; MELANOMA CELL; MELANOMA METASTASIS; METASTASIS INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; NORADRENALIN BLOOD LEVEL; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CORTICOSTERONE; DNA PROBES; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTATHIONE; IN SITU HYBRIDIZATION; INTERLEUKIN-6; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; NOREPINEPHRINE; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84875149663     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-72     Document Type: Article

References (66)

1. Meister A. Selective modification of glutathione metabolism. Science 1983, 220:472-477. 10.1126/science.6836290, 6836290.
2. Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 2006, 43:143-181. 10.1080/10408360500523878, 16517421.
3. Ortega A, Mena S, Estrela JM. Glutathione in cancer cell death. Cancers 2001, 3:1285-1310.
4. Obrador E, Benlloch M, Pellicer JA, Asensi M, Estrela JM. Intertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice. J Biol Chem 2011, 286:15716-15727. 10.1074/jbc.M110.196261, 3091180, 21393247.
5. Zhang H, Forman HJ, Choi J. Gamma-glutamyl transpeptidase in glutathione biosynthesis. Methods Enzymol 2005, 401:468-483.
6. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 1991, 51:155-194. 10.1016/0163-7258(91)90076-X, 1784629.
7. Hanigan MH. Expression of gamma-glutamyl transpeptidase provides tumor cells with a selective growth advantage at physiologic concentrations of cyst(e)ine. Carcinogenesis 1995, 16:181-185. 10.1093/carcin/16.2.181, 7859346.
8. Obrador E, Carretero J, Ortega A, Medina I, Rodilla V, Pellicer JA, Estrela JM. gamma-Glutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. Hepatology 2002, 35:74-81. 10.1053/jhep.2002.30277, 11786961.
9. Ballatori N, Rebbeor JF. Roles of MRP2 and oatp1 in hepatocellular export of reduced glutathione. Semin Liver Dis 1998, 18:377-387. 10.1055/s-2007-1007171, 9875555.
10. Hodg DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005, 41:2502-2512. 10.1016/j.ejca.2005.08.016, 16199153.
11. Barton BE. Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert Opin Ther Targets 2005, 9:737-752. 10.1517/14728222.9.4.737, 16083340.
12. Rose-John S, Waetzig GH, Scheller J, Grötzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007, 11:613-624. 10.1517/14728222.11.5.613, 17465721.
13. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010, 46:1223-1231. 10.1016/j.ejca.2010.02.026, 2917917, 20335016.
14. Emmenegger U, Kerbel RS. Cancer Chemotherapy counteracted. Nature 2010, 468:637-638. 10.1038/468637a, 21124441.
15. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, Li LZ. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010, 295:110-123. 10.1016/j.canlet.2010.02.019, 20236757.
16. Sternberg EM. Neural-immune interactions in health and disease. J Clin Invest 1997, 100:2641-2647. 10.1172/JCI119807, 508465, 9389725.
17. Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol 2004, 5:617-625. 10.1016/S1470-2045(04)01597-9, 15465465.
18. Besedovsky HO, Del Rey A, Klusman I, Furukawa H, Monge Arditi G, Kabiersch A. Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. J Steroid Biochem Mol Biol 1991, 40:613-618. 10.1016/0960-0760(91)90284-C, 1659887.
19. Bethin KE, Vogt SK, Muglia LJ. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci USA 2000, 97:9317-9322. 10.1073/pnas.97.16.9317, 16865, 10922080.
20. Fauci AS. Mechanisms of the immunosuppressive and anti-inflammatory effects of glucocorticosteroids. J Immunopharmacol 1978, 1:1-25.
21. Herr I, Pfitzenmaier J. Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 2006, 7:425-430. 10.1016/S1470-2045(06)70694-5, 16648047.
22. Bernabé DG, Tamae AC, Biasoli T, Oliveira SH. Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells. Brain Behav Immun 2011, 25:574-583. 10.1016/j.bbi.2010.12.012, 21187140.
23. Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 2006, 6:240-248. 10.1038/nrc1820, 3146042, 16498446.
24. Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, Barsky SH, Glaser R. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009, 23:267-275. 10.1016/j.bbi.2008.10.005, 2652747, 18996182.
25. Carretero J, Obrador E, Anasagasti MJ, Martin JJ, Vidal-Vanaclocha F, Estrela JM. Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells. Clin Exp Metastasis 1999, 17:567-574. 10.1023/A:1006725226078, 10845555.
26. Lachize S, Apostolakis EM, van der Laan S, Tijssen AM, Xu J, de Kloet ER, Meijer OC. Steroid receptor coactivator-1 is necessary for regulation of corticotropin-releasing hormone by chronic stress and glucocorticoids. Proc Natl Acad Sci USA 2009, 106:8038-8042. 10.1073/pnas.0812062106, 2683087, 19416907.
27. Veenema AH, Reber SO, Selch S, Obermeier F, Neumann ID. Early life stress enhances the vulnerability to chronic psychosocial stress and experimental colitis in adult mice. Endocrinology 2008, 149:2727-2736. 10.1210/en.2007-1469, 18308845.
28. New LS, Chan EC. Evaluation of BEH C18, BEH HILIC, and HSS T3 (C18) column chemistries for the UPLC-MS-MS analysis of glutathione, glutathione disulfide, and ophthalmic acid in mouse liver and human plasma. Chromatogr Sci 2008, 46:209-214.
29. Asensi M, Sastre J, Pallardo FV, Garcia De La Asuncion J, Estrela JM, Vina JA. High-performance liquid chromatography method for measurement of oxidized glutathione in biological samples. Anal Biochem 1994, 217:323-328. 10.1006/abio.1994.1126, 8203763.
30. Benlloch M, Mena S, Ferrer P, Obrador E, Asensi M, Pellicer JA, Carretero J, Ortega A, Estrela JM. Bcl-2 and Mn-SOD antisense oligodeoxynucleotides and a glutamine-enriched diet facilitate elimination of highly resistant B16 melanoma cells by tumor necrosis factor-alpha and chemotherapy. J Biol Chem 2006, 281:69-79.
31. Ortega AL, Carretero J, Obrador E, Gambini J, Asensi M, Rodilla V, Estrela JM. Tumor cytotoxicity by endothelial cells. Impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after in vitro interaction with the hepatic sinusoidal endothelium. J Biol Chem 2003, 278:13888-13897. 10.1074/jbc.M207140200, 12578841.
32. Sakakibara H, Koyanagi A, Suzuki T, Suzuki A, Ling L, Shimoi K. Effects of animal care procedures on plasma corticosterone levels in group-housed mice during the nocturnal active phase. Exp Anim 2010, 59:637-642. 10.1538/expanim.59.637, 21030792.
33. Lucot JB, Jackson N, Bernatova I, Morris M. Measurement of plasma catecholamines in small samples from mice. J Pharmacol Toxicol Methods 2005, 52:274-277. 10.1016/j.vascn.2004.11.004, 16125626.
34. Dobos J, Kenessey I, Tímár J, Ladányi A. Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells. Pathol Oncol Res 2011, 17:729-734. 10.1007/s12253-011-9377-8, 21455635.
35. Ristic-Fira A, Vujcic M, Krstic-Demonacos M, Kanazir D. Identification and characterization of glucocorticoid receptors in B16 mouse melanoma cells. Endocr Regul 1999, 33:109-115.
36. Tsuji M, Kuno T, Tanaka C, Ichihashi M, Mishima Y. Beta-adrenergic receptors of B16 melanoma cell. Arch Dermatol Res 1983, 275:415-416. 10.1007/BF00417345, 6318672.
37. Im A, Appleman LJ. Mifepristone: pharmacology and clinical impact in reproductive medicine, endocrinology and oncology. Expert Opin Pharmacother 2010, 11:481-488. 10.1517/14656560903535880, 20102310.
38. Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy?. Oncotarget 2010, 1:466-469. 3248132, 21317444.
39. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Aging Dev 2004, 125:697-706. 10.1016/j.mad.2004.06.010, 15541765.
40. Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 2012, 18:1201-1206. 10.1158/1078-0432.CCR-11-0641, 3294063, 22186256.
41. Boutillier AL, Barthel F, Roberts JL, Loeffler JP. Beta-adrenergic stimulation of cFOS via protein kinase A is mediated by cAMP regulatory element binding protein (CREB)-dependent and tissue-specific CREB-independent mechanisms in corticotrope cells. J Biol Chem 1992, 267:23520-23526.
42. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T, Akira S. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci USA 1993, 90:10193-10197. 10.1073/pnas.90.21.10193, 47740, 8234276.
43. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007, 87:873-904. 10.1152/physrev.00041.2006, 17615391.
44. Turnbull A, Prehar S, Kennedy A, Little R, Hopkins S. Interleukin-6 is an afferent signal to the hypothalamo-pituitary-adrenal axis during local inflammation in mice. Endocrinol 2003, 144:1894-1906.
45. Lee JH, Yoo SB, Kim NY, Cha MJ, Jahng JW. Interleukin-6 and the hypothalamic-pituitary-adrenal activation in a tumor bearing mouse. Int J Neurosci 2008, 118:355-364. 10.1080/00207450701592915, 18300009.
46. Kageyama K, Tamasawa N, Suda T. Signal transduction in the hypothalamic corticotropin-releasing factor system and its clinical implications. Stress 2011, 14:357-367.
47. Li YF, He RR, Tsoi B, Li XD, Li WX, Abe K, Kurihara H. Anti-stress effects of carnosine on restraint-evoked immunocompromise in mice through spleen lymphocyte number maintenance. PLoS One 2012, 7:e33190. 10.1371/journal.pone.0033190, 3325237, 22511917.
48. Sarabdjitsingh RA, Kofink D, Karst H, de Kloet ER, Joëls M. Stress-induced enhancement of mouse amygdalar synaptic plasticity depends on glucocorticoid and ß-adrenergic activity. PLoS One 2012, 7:e42143. 10.1371/journal.pone.0042143, 3416843, 22900007.
49. Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol 2010, 6:1863-1881. 10.2217/fon.10.142, 3037818, 21142861.
50. Tissing WJ, Meijerink JP, den Boer ML, Pieters R. Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 2003, 17:17-25. 10.1038/sj.leu.2402733, 12529655.
51. Maung ZT, Hogarth L, Reid MM, Proctor SJ, Hamilton PJ, Hall AG. Raised intracellular glutathione levels correlate with in vitro resistance to cytotoxic drugs in leukaemic cells from patients with acute lymphoblastic leukemia. Leukemia 1994, 8:1487-1491.
52. Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Welte K, Stanulla M. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000, 10:715-726. 10.1097/00008571-200011000-00006, 11186134.
53. Thaker PH, Sood AK. Neuroendocrine influences on cancer biology. Semin Cancer Biol 2008, 18:164-170. 10.1016/j.semcancer.2007.12.005, 2424028, 18201896.
54. Snyers L, De Wit L, Content J. Glucocorticoid up-regulation of high-affinity interleukin 6 receptors on human epithelial cells. Proc Natl Acad Sci USA 1990, 7:2838-2842.
55. Takeda T, Kurachi H, Yamamoto T, Nishio Y, Nakatsuji Y, Morishige K-I, Miyake A, Murata Y. Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoid. J Endocrinol 1998, 159:323-330. 10.1677/joe.0.1590323, 9795374.
56. Franco R, Cidlowski JA. Glutathione efflux and cell death. Antioxid Redox Signal 2012, 17:1676-1693. 10.1089/ars.2011.4474, 22816731.
57. Tome ME, Jaramillo MC, Briehl MM. Hydrogen peroxide signaling is required for glucocorticoid-induced apoptosis in lymphoma cells. Free Radic Biol Med 2011, 51:2048-2059. 10.1016/j.freeradbiomed.2011.09.002, 3208737, 21964507.
58. Lázár-Molnár E, Hegyesi H, Tóth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000, 12:547-554. 10.1006/cyto.1999.0614, 10843728.
59. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012, 30:1005-1014. 10.1200/JCO.2010.31.8907, 3341105, 22355058.
60. Arrigo AP. Gene expression and the thiol redox state. Free Radic Biol Med 1999, 27:936-944. 10.1016/S0891-5849(99)00175-6, 10569626.
61. Antelmann H, Helmann JD. Thiol-based redox switches and gene regulation. Antioxid Redox Signal 2011, 14:1049-1063. 10.1089/ars.2010.3400, 3113447, 20626317.
62. Leibowitz B, Yu J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 2010, 9:417-422. 10.4161/cbt.9.6.11392, 2874116, 20190564.
63. Mancino M, Ametller E, Gascón P, Almendro V. The neuronal influence on tumor progression. Biochim Biophys Acta 1816, 2011:105-118.
64. Powe DG, Voss MJ, Habashy HO, Zänker KS, Green AR, Ellis IO, Entschladen F. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat 2011, 130:457-463. 10.1007/s10549-011-1371-z, 21298476.
65. Powe DG, Entschladen F. Targeted therapies: Using β-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 2011, 8:511-512. 10.1038/nrclinonc.2011.123, 21808268.
66. Min KJ, Jang J, Lee JT, Choi KS, Kwon TK. Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. J Mol Med (Berl) 2012, 90:309-319.